Rafarma Pharmaceuticals (RAFA) Stock Price, News & Analysis
Company Description
Rafarma Pharmaceuticals (OTC Link: RAFA) is a publicly traded drug manufacturers - specialty & generic company in the Healthcare sector. The company has a market capitalization of $8.6M.
RAFA stock has gained 3.1% over the past year. Shares last traded at $0.0400.
This page provides a comprehensive overview of RAFA stock, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Rafarma Pharmaceuticals (RAFA) stock last traded at $0.0400. Over the past 12 months, the stock has gained 3.1%. At a market capitalization of $8.6M, RAFA is classified as a micro-cap stock with approximately 87.8M shares outstanding.
Latest News
Rafarma Pharmaceuticals has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. View all RAFA news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Rafarma Pharmaceuticals (RAFA) currently stands at 149 shares, representing 0.0% of the shares outstanding. Over the past 12 months, short interest has decreased by 97.6%.
Days to Cover History
Days to cover for Rafarma Pharmaceuticals (RAFA) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 3.0 days.
RAFA Company Profile & Sector Positioning
Rafarma Pharmaceuticals (RAFA) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing RAFA often look at related companies in the same sector, including Full Alliance Group Inc (FAGI), Medicure (MCUJF), Nextleaf Solutions Ltd (OILFF), One World Produc (OWPC), and Christina Lake C (CLCFF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RAFA's relative position within its industry.